SCHEMBL2999562

SCHEMBL2999562

COC(=O)C1=C(C)Nc2nnnn2C1c1c(Br)sc2ccc(Cl)cc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
HPGD P15428 3/20 0.54
HTT P42858 1/20 0.54
NPSR1 Q6W5P4 4/20 0.51
LMNA P02545 6/20 0.47
TSHR P16473 1/20 0.47
MAPT P10636 4/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
TP53 P04637 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP2D6 P10635 1/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
USP2 O75604 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2995959 0.88 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2HPGDHTTNPSR1
SCHEMBL3002781 0.79 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2HPGDHTTNPSR1
SCHEMBL2995850 0.78 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2HPGDHTTNPSR1
SCHEMBL3003501 0.77 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2HPGDHTTNPSR1
SCHEMBL3263087 0.77 ALDH1A1 (0.48) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL3003474 0.76 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2HPGDHTTNPSR1
SCHEMBL2999401 0.76 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2HPGDHTTNPSR1
SCHEMBL2996987 0.76 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2HPGDHTTNPSR1
SCHEMBL3006666 0.74 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2HPGDHTTNPSR1
SCHEMBL2990618 0.72 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2HPGDHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045428-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2015-06-02 US disclosed
US-8716319-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-05-06 US disclosed
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-12-05 US disclosed
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-08-05 US disclosed
WO-2010002483-A1 OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS CV THERAPEUTICS, INC. (US) 2010-01-07 WO disclosed
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. 2009-07-16 US disclosed
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. 2009-01-08 US disclosed
WO-2009006580-A1 OPTIONALLY CONDENSED DIHYDROPYRIDINE, DIHYDROPYRIMIDINE AND DIHYDROPYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS CV THERAPEUTICS, INC. (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885SMN1; SMN2 1739/4885HPGD 280/4885
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885SMN1; SMN2 1739/4885HPGD 280/4885
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885SMN1; SMN2 1739/4885HPGD 280/4885
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885SMN1; SMN2 1739/4885HPGD 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.